Submitted:
08 July 2026
Posted:
09 July 2026
You are already at the latest version
Abstract

Keywords:
1. Introduction
2. Metabolic Endogenous Neurotoxins and Their Systemic Disease Interfaces
2.1. Ammonia and Nitrogen Dysregulation
2.2. Homocysteine and One-Carbon Metabolism
2.3. Advanced Glycation End Products (AGEs)
3. Neurotransmitter-Derived Toxicity
3.1. Glutamate Excitotoxicity
3.1.1. NMDA/AMPA Receptor Overactivation
3.1.2. Calcium Influx and Mitochondrial Dysfunction
3.1.3. Astrocytic Glutamate Clearance Failure
3.2. Dopamine Oxidation and Quinone Formation
3.2.1. Auto-Oxidation and Enzymatic Metabolism
3.2.2. Generation of Reactive Quinones and Reactive Oxygen Species
3.2.3. Selective Vulnerability of Dopaminergic Neurons
4. Protein Aggregates as Endogenous Neurotoxic Species
4.1. Amyloid-β Toxicity
4.1.1. Imbalance Between Amyloid-β Production and Clearance
4.1.2. Synaptic Dysfunction, Membrane Disruption and Neuronal Stress
4.2. α-Synuclein Misfolding and Proteostatic Stress
4.2.1. Misfolding, Oligomerization and Aggregation
4.2.2. Membrane Interactions, Vesicular Trafficking and Mitochondrial Dysfunction
4.3. Tau Dysfunction and Cytoskeleton Instability
4.3.1. Hyperphosphorylation and Microtubule Destabilization
4.3.2. Propagation of Tau Pathology Across Neuronal Networks
4.3.3. Toxic Oligomers Versus Fibrillar Aggregates
5. Convergent Cellular Mechanisms of Endogenous Neurotoxicity
5.1. Oxidative Stress and Redox Imbalance
5.1.1. Generation of Reactive Oxygen and Nitrogen Species
5.1.2. Oxidative Damage to Lipids, Proteins, and DNA
5.1.3. Failure of Endogenous Antioxidant Defenses
5.2. Mitochondrial Dysfunction
5.2.1. Impaired Bioenergetics and ATP Depletion
5.2.2. Calcium Dysregulation and Mitochondrial Permeability Transition
5.2.3. Mitochondrial Reactive Oxygen Species and Amplification of Neurotoxicity
5.3. Proteostasis Failure and Cellular Stress Responses
5.3.1. Ubiquitin-Proteasome Dysfunction
5.3.2. Autophagy-Lysosomal Impairment
5.3.3. Endoplasmic Reticulum Stress and the Unfolded Protein Response
6. Neuroglial Dysfunction in Endogenous Neurotoxicity
6.1. Astrocytic Dysfunction and Loss of Homeostasis
6.1.1. Glutamate Clearance and Excitatory Homeostasis
6.1.2. Metabolic Coupling and Neuronal Support
6.1.3. Reactive Astrocyte Phenotypes
6.2. Microglial Activation and Neuroinflammation
6.2.1. Innate Immune Activation and Inflammatory Signaling
6.2.2. Phagocytosis, Synaptic Remodeling and Synaptic Stripping
6.2.3. Chronic Activation and Amplification of Neurotoxicity
6.3. Oligodendrocyte Vulnerability and White Matter Dysfunction
6.3.1. Susceptibility to Oxidative and Metabolic Stress
6.3.2. Myelin Maintenance and Axonal Metabolic Support
6.3.3. Neuroglial Crosstalk and Failure of Brain Homeostasis
7. Clinical and Translational Implications
7.1. Endogenous Neurotoxicity as a Common Mechanism in Neurodegenerative Disorders
7.2. Biomarkers of Endogenous Neurotoxicity
7.3. Restoring Homeostasis: Therapeutic Strategies Against Endogenous Neurotoxicity
8. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
| 4-HNE | 4-Hydroxynonenal |
| 8-OHdG | 8-Hydroxy-2′-deoxyguanosine |
| AGEs | Advanced glycation end products |
| AMPA | α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid |
| Aβ | Amyloid-β |
| BBB | Blood-brain Barrier |
| CNS | Central Nervous System |
| COMT | Catechol-O-methyltransferase |
| DOPAL | 3,4-dihydroxyphenylacetaldehyde |
| ER | Endoplasmic reticulum |
| ERAD | ER-associated degradation |
| GSH | Reduced glutathione |
| MAO | Monoamine oxidase |
| MDA | Malondialdehyde |
| NfL | Neurofilament light chain |
| NMDA | N-methyl-D-aspartate |
| p-tau | Phosphorylated tau |
| RAGE | Receptor for advanced glycation end products |
| RNS | Reactive nitrogen species |
| ROS | Reactive Oxygen Species |
| TSPO | Translocator Protein |
| UPR | Unfolded protein response |
| UPS | Ubiquitin-proteasome system |
| VMAT2 | Vesicular monoamine transporter-2 |
References
- Cao, Y.; Li, B.; Ismail, N.; Smith, K.; Li, T.; Dai, R.; Deng, Y. Neurotoxicity and Underlying Mechanisms of Endogenous Neurotoxins. IJMS 2021, 22, 12805. [CrossRef]
- Wang Selective Neuronal Vulnerability to Oxidative Stress in the Brain. Fronti.Ag.Neurosci. 2010. [CrossRef]
- Liddelow, S.A.; Barres, B.A. Reactive Astrocytes: Production, Function, and Therapeutic Potential. Immunity 2017, 46, 957–967. [CrossRef]
- Escartin, C.; Galea, E.; Lakatos, A.; O’Callaghan, J.P.; Petzold, G.C.; Serrano-Pozo, A.; Steinhäuser, C.; Volterra, A.; Carmignoto, G.; Agarwal, A.; et al. Reactive Astrocyte Nomenclature, Definitions, and Future Directions. Nat Neurosci 2021, 24, 312–325. [CrossRef]
- Salter, M.W.; Stevens, B. Microglia Emerge as Central Players in Brain Disease. Nat Med 2017, 23, 1018–1027. [CrossRef]
- Surmeier, D.J.; Obeso, J.A.; Halliday, G.M. Selective Neuronal Vulnerability in Parkinson Disease. Nat Rev Neurosci 2017, 18, 101–113. [CrossRef]
- Selkoe, D.J.; Hardy, J. The Amyloid Hypothesis of Alzheimer’s Disease at 25 Years. EMBO Mol Med 2016, 8, 595–608. [CrossRef]
- Prinz, M.; Masuda, T.; Wheeler, M.A.; Quintana, F.J. Microglia and Central Nervous System–Associated Macrophages—From Origin to Disease Modulation. Annu. Rev. Immunol. 2021, 39, 251–277. [CrossRef]
- DiSabato, D.J.; Quan, N.; Godbout, J.P. Neuroinflammation: The Devil Is in the Details. Journal of Neurochemistry 2016, 139, 136–153. [CrossRef]
- Mithaiwala, M.N.; Santana-Coelho, D.; Porter, G.A.; O’Connor, J.C. Neuroinflammation and the Kynurenine Pathway in CNS Disease: Molecular Mechanisms and Therapeutic Implications. Cells 2021, 10, 1548. [CrossRef]
- Hayden, M.; Tyagi, S. Impaired Folate-Mediated One-Carbon Metabolism in Type 2 Diabetes, Late-Onset Alzheimer’s Disease and Long COVID. Medicina 2021, 58, 16. [CrossRef]
- Tapper, E.B.; Jiang, Z.G.; Patwardhan, V.R. Refining the Ammonia Hypothesis. Mayo Clinic Proceedings 2015, 90, 646–658. [CrossRef]
- Lu, K. Cellular Pathogenesis of Hepatic Encephalopathy: An Update. Biomolecules 2023, 13, 396. [CrossRef]
- Moretti, R.; Caruso, P. The Controversial Role of Homocysteine in Neurology: From Labs to Clinical Practice. IJMS 2019, 20, 231. [CrossRef]
- Vilstrup, H.; Eriksen, P.L.; Kjærgaard, K.; Sørensen, M.; Thomsen, K.L.; Ott, P. Down the Road towards Hepatic Encephalopathy. Urea Synthesis - the Liver Workhorse of Nitrogen Metabolism. Metab Brain Dis 2024, 40, 49. [CrossRef]
- Häussinger, D.; Dhiman, R.K.; Felipo, V.; Görg, B.; Jalan, R.; Kircheis, G.; Merli, M.; Montagnese, S.; Romero-Gomez, M.; Schnitzler, A.; et al. Hepatic Encephalopathy. Nat Rev Dis Primers 2022, 8, 43. [CrossRef]
- Segura-Bruna, N.; Rodriguez-Campello, A.; Puente, V.; Roquer, J. Valproate-Induced Hyperammonemic Encephalopathy. Acta Neurol Scand 2006, 114, 1–7. [CrossRef]
- Limón, I.D.; Angulo-Cruz, I.; Sánchez-Abdon, L.; Patricio-Martínez, A. Disturbance of the Glutamate-Glutamine Cycle, Secondary to Hepatic Damage, Compromises Memory Function. Front. Neurosci. 2021, 15, 578922. [CrossRef]
- Zielińska, M.; Albrecht, J.; Popek, M. Dysregulation of Astrocytic Glutamine Transport in Acute Hyperammonemic Brain Edema. Front. Neurosci. 2022, 16, 874750. [CrossRef]
- Rama Rao, K.V.; Reddy, P.V.B.; Tong, X.; Norenberg, M.D. Brain Edema in Acute Liver Failure. The American Journal of Pathology 2010, 176, 1400–1408. [CrossRef]
- Dayon, L.; Guiraud, S.P.; Corthésy, J.; Da Silva, L.; Migliavacca, E.; Tautvydaitė, D.; Oikonomidi, A.; Moullet, B.; Henry, H.; Métairon, S.; et al. One-Carbon Metabolism, Cognitive Impairment and CSF Measures of Alzheimer Pathology: Homocysteine and Beyond. Alz Res Therapy 2017, 9, 43. [CrossRef]
- Cassar, S.; Adatto, I.; Freeman, J.L.; Gamse, J.T.; Iturria, I.; Lawrence, C.; Muriana, A.; Peterson, R.T.; Van Cruchten, S.; Zon, L.I. Use of Zebrafish in Drug Discovery Toxicology. Chem. Res. Toxicol. 2020, 33, 95–118. [CrossRef]
- Esse, R.; Barroso, M.; Tavares De Almeida, I.; Castro, R. The Contribution of Homocysteine Metabolism Disruption to Endothelial Dysfunction: State-of-the-Art. IJMS 2019, 20, 867. [CrossRef]
- An, Y.; Feng, L.; Zhang, X.; Wang, Y.; Wang, Y.; Tao, L.; Qin, Z.; Xiao, R. Dietary Intakes and Biomarker Patterns of Folate, Vitamin B6, and Vitamin B12 Can Be Associated with Cognitive Impairment by Hypermethylation of Redox-Related Genes NUDT15 and TXNRD1. Clin Epigenet 2019, 11, 139. [CrossRef]
- Li, S.; Li, G.; Luo, X.; Huang, Y.; Wen, L.; Li, J. Endothelial Dysfunction and Hyperhomocysteinemia-Linked Cerebral Small Vessel Disease: Underlying Mechanisms and Treatment Timing. Front. Neurol. 2021, 12, 736309. [CrossRef]
- Braun, D.J.; Abner, E.; Bakshi, V.; Goulding, D.S.; Grau, E.M.; Lin, A.-L.; Norris, C.M.; Sudduth, T.L.; Webster, S.J.; Wilcock, D.M.; et al. Blood Flow Deficits and Cerebrovascular Changes in a Dietary Model of Hyperhomocysteinemia. ASN Neuro 2019, 11, 1759091419865788. [CrossRef]
- Ungvari, A.; Gulej, R.; Csik, B.; Mukli, P.; Negri, S.; Tarantini, S.; Yabluchanskiy, A.; Benyo, Z.; Csiszar, A.; Ungvari, Z. The Role of Methionine-Rich Diet in Unhealthy Cerebrovascular and Brain Aging: Mechanisms and Implications for Cognitive Impairment. Nutrients 2023, 15, 4662. [CrossRef]
- Carey, A.; Parodi-Rullan, R.; Vazquez-Torres, R.; Canepa, E.; Fossati, S. Homocysteine Potentiates Amyloid B-induced Death Receptor 4- and 5-mediated Cerebral Endothelial Cell Apoptosis, Blood Brain Barrier Dysfunction and Angiogenic Impairment. Aging Cell 2024, 23, e14106. [CrossRef]
- Reddy, V.P.; Aryal, P.; Darkwah, E.K. Advanced Glycation End Products in Health and Disease. Microorganisms 2022, 10, 1848. [CrossRef]
- Mengstie, M.A.; Chekol Abebe, E.; Behaile Teklemariam, A.; Tilahun Mulu, A.; Agidew, M.M.; Teshome Azezew, M.; Zewde, E.A.; Agegnehu Teshome, A. Endogenous Advanced Glycation End Products in the Pathogenesis of Chronic Diabetic Complications. Front. Mol. Biosci. 2022, 9, 1002710. [CrossRef]
- Fishman, S.L.; Sonmez, H.; Basman, C.; Singh, V.; Poretsky, L. The Role of Advanced Glycation End-Products in the Development of Coronary Artery Disease in Patients with and without Diabetes Mellitus: A Review. Mol Med 2018, 24, 59. [CrossRef]
- Brouwers, O.; Niessen, P.M.; Ferreira, I.; Miyata, T.; Scheffer, P.G.; Teerlink, T.; Schrauwen, P.; Brownlee, M.; Stehouwer, C.D.; Schalkwijk, C.G. Overexpression of Glyoxalase-I Reduces Hyperglycemia-Induced Levels of Advanced Glycation End Products and Oxidative Stress in Diabetic Rats. Journal of Biological Chemistry 2011, 286, 1374–1380. [CrossRef]
- Boccardi, V.; Mancinetti, F.; Mecocci, P. Oxidative Stress, Advanced Glycation End Products (AGEs), and Neurodegeneration in Alzheimer’s Disease: A Metabolic Perspective. Antioxidants 2025, 14, 1044. [CrossRef]
- Armada-Moreira, A.; Gomes, J.I.; Pina, C.C.; Savchak, O.K.; Gonçalves-Ribeiro, J.; Rei, N.; Pinto, S.; Morais, T.P.; Martins, R.S.; Ribeiro, F.F.; et al. Going the Extra (Synaptic) Mile: Excitotoxicity as the Road Toward Neurodegenerative Diseases. Front. Cell. Neurosci. 2020, 14, 90. [CrossRef]
- Mahmoud, S.; Gharagozloo, M.; Simard, C.; Gris, D. Astrocytes Maintain Glutamate Homeostasis in the CNS by Controlling the Balance between Glutamate Uptake and Release. Cells 2019, 8, 184. [CrossRef]
- Zhang, K.; Wen, M.; Nan, X.; Zhao, S.; Li, H.; Ai, Y.; Zhu, H. NMDA Receptors in Neurodegenerative Diseases: Mechanisms and Emerging Therapeutic Strategies. Front. Aging Neurosci. 2025, 17, 1604378. [CrossRef]
- Guo, C.; Ma, Y.-Y. Calcium Permeable-AMPA Receptors and Excitotoxicity in Neurological Disorders. Front. Neural Circuits 2021, 15, 711564. [CrossRef]
- Yu, S.P.; Jiang, M.Q.; Shim, S.S.; Pourkhodadad, S.; Wei, L. Extrasynaptic NMDA Receptors in Acute and Chronic Excitotoxicity: Implications for Preventive Treatments of Ischemic Stroke and Late-Onset Alzheimer’s Disease. Mol Neurodegeneration 2023, 18, 43. [CrossRef]
- Arnold, F.J.; Putka, A.F.; Raychaudhuri, U.; Hsu, S.; Bedlack, R.S.; Bennett, C.L.; La Spada, A.R. Revisiting Glutamate Excitotoxicity in Amyotrophic Lateral Sclerosis and Age-Related Neurodegeneration. IJMS 2024, 25, 5587. [CrossRef]
- Kandy, S.K.; Nimonkar, M.M.; Dash, S.S.; Mehta, B.; Markandeya, Y.S. Astaxanthin Protection against Neuronal Excitotoxicity via Glutamate Receptor Inhibition and Improvement of Mitochondrial Function. Marine Drugs 2022, 20, 645. [CrossRef]
- Gut, I.M.; Beske, P.H.; Hubbard, K.S.; Lyman, M.E.; Hamilton, T.A.; McNutt, P.M. Novel Application of Stem Cell-Derived Neurons to Evaluate the Time- and Dose-Dependent Progression of Excitotoxic Injury. PLoS ONE 2013, 8, e64423. [CrossRef]
- Belov Kirdajova, D.; Kriska, J.; Tureckova, J.; Anderova, M. Ischemia-Triggered Glutamate Excitotoxicity From the Perspective of Glial Cells. Front. Cell. Neurosci. 2020, 14, 51. [CrossRef]
- Segura-Aguilar, J.; Paris, I.; Muñoz, P.; Ferrari, E.; Zecca, L.; Zucca, F.A. Protective and Toxic Roles of Dopamine in Parkinson’s Disease. Journal of Neurochemistry 2014, 129, 898–915. [CrossRef]
- Bisaglia, M.; Mammi, S.; Bubacco, L. Kinetic and Structural Analysis of the Early Oxidation Products of Dopamine. Journal of Biological Chemistry 2007, 282, 15597–15605. [CrossRef]
- Goldstein, D.S. The Catecholaldehyde Hypothesis: Where MAO Fits In. J Neural Transm 2020, 127, 169–177. [CrossRef]
- Hwang, O. Role of Oxidative Stress in Parkinson’s Disease. Exp Neurobiol 2013, 22, 11–17. [CrossRef]
- Burbulla, L.F.; Song, P.; Mazzulli, J.R.; Zampese, E.; Wong, Y.C.; Jeon, S.; Santos, D.P.; Blanz, J.; Obermaier, C.D.; Strojny, C.; et al. Dopamine Oxidation Mediates Mitochondrial and Lysosomal Dysfunction in Parkinson’s Disease. Science 2017, 357, 1255–1261. [CrossRef]
- Jiang, S.; Bhaskar, K. Degradation and Transmission of Tau by Autophagic-Endolysosomal Networks and Potential Therapeutic Targets for Tauopathy. Front. Mol. Neurosci. 2020, 13, 586731. [CrossRef]
- Guo, T.; Noble, W.; Hanger, D.P. Roles of Tau Protein in Health and Disease. Acta Neuropathol 2017, 133, 665–704. [CrossRef]
- Bernal-Conde, L.D.; Ramos-Acevedo, R.; Reyes-Hernández, M.A.; Balbuena-Olvera, A.J.; Morales-Moreno, I.D.; Argüero-Sánchez, R.; Schüle, B.; Guerra-Crespo, M. Alpha-Synuclein Physiology and Pathology: A Perspective on Cellular Structures and Organelles. Front. Neurosci. 2020, 13, 1399. [CrossRef]
- Azargoonjahromi, A. The Duality of Amyloid-β: Its Role in Normal and Alzheimer’s Disease States. Mol Brain 2024, 17, 44. [CrossRef]
- Chen, G.; Xu, T.; Yan, Y.; Zhou, Y.; Jiang, Y.; Melcher, K.; Xu, H.E. Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development. Acta Pharmacol Sin 2017, 38, 1205–1235. [CrossRef]
- Zhang, Y.-L.; Wang, J.; Zhang, Z.-N.; Su, Q.; Guo, J.-H. The Relationship between Amyloid-Beta and Brain Capillary Endothelial Cells in Alzheimer’s Disease. Neural Regen Res 2022, 17, 2355. [CrossRef]
- Karisetty, B.C.; Bhatnagar, A.; Armour, E.M.; Beaver, M.; Zhang, H.; Elefant, F. Amyloid-β Peptide Impact on Synaptic Function and Neuroepigenetic Gene Control Reveal New Therapeutic Strategies for Alzheimer’s Disease. Front. Mol. Neurosci. 2020, 13, 577622. [CrossRef]
- Njoku, G.C.; Kanmogne, G.D. Microglial Dysfunction and Amyloid-Beta Pathology in Alzheimer’s Disease and HIV-Associated Neurocognitive Disorders. IJMS 2025, 26, 9069. [CrossRef]
- Mucke, L.; Selkoe, D.J. Neurotoxicity of Amyloid -Protein: Synaptic and Network Dysfunction. Cold Spring Harbor Perspectives in Medicine 2012, 2, a006338–a006338. [CrossRef]
- Toruński, P.; Pizzirusso, G.; Winblad, B.; Arroyo-García, L.E. Decoding the Mechanisms of Amyloid-β in Synaptic Toxicity. Journal of Alzheimer’s Disease 2026, 110, 1560–1583. [CrossRef]
- Behroozi, Z.; Askarpour, H.; Baghcheghi, Y. Molecular Sabotage of Hippocampal Synaptic Plasticity by Amyloid-β in Alzheimer’s Disease: A Narrative Review. Journal of Alzheimer’s Disease Reports 2026, 10, 25424823261415807. [CrossRef]
- Meng, X.; Song, Q.; Liu, Z.; Liu, X.; Wang, Y.; Liu, J. Neurotoxic β-Amyloid Oligomers Cause Mitochondrial Dysfunction—the Trigger for PANoptosis in Neurons. Front. Aging Neurosci. 2024, 16, 1400544. [CrossRef]
- Massaro, M.; Baudo, G.; Lee, H.; Liu, H.; Blanco, E. Nuclear Respiratory Factor-1 (NRF1) Induction Drives Mitochondrial Biogenesis and Attenuates Amyloid Beta-Induced Mitochondrial Dysfunction and Neurotoxicity. Neurotherapeutics 2025, 22, e00513. [CrossRef]
- Olajide, O.J.; La Rue, C.; Bergdahl, A.; Chapman, C.A. Inhibiting Amyloid Beta (1–42) Peptide-Induced Mitochondrial Dysfunction Prevents the Degradation of Synaptic Proteins in the Entorhinal Cortex. Front. Aging Neurosci. 2022, 14, 960314. [CrossRef]
- Alberdi, E.; Sánchez-Gómez, M.V.; Ruiz, A.; Cavaliere, F.; Ortiz-Sanz, C.; Quintela-López, T.; Capetillo-Zarate, E.; Solé-Domènech, S.; Matute, C. Mangiferin and Morin Attenuate Oxidative Stress, Mitochondrial Dysfunction, and Neurocytotoxicity, Induced by Amyloid Beta Oligomers. Oxidative Medicine and Cellular Longevity 2018, 2018, 2856063. [CrossRef]
- Ottolini, D.; Calí, T.; Szabò, I.; Brini, M. Alpha-Synuclein at the Intracellular and the Extracellular Side: Functional and Dysfunctional Implications. Biological Chemistry 2017, 398, 77–100. [CrossRef]
- Iljina, M.; Garcia, G.A.; Horrocks, M.H.; Tosatto, L.; Choi, M.L.; Ganzinger, K.A.; Abramov, A.Y.; Gandhi, S.; Wood, N.W.; Cremades, N.; et al. Kinetic Model of the Aggregation of Alpha-Synuclein Provides Insights into Prion-like Spreading. Proc. Natl. Acad. Sci. U.S.A. 2016, 113. [CrossRef]
- Cremades, N.; Cohen, S.I.A.; Deas, E.; Abramov, A.Y.; Chen, A.Y.; Orte, A.; Sandal, M.; Clarke, R.W.; Dunne, P.; Aprile, F.A.; et al. Direct Observation of the Interconversion of Normal and Toxic Forms of α-Synuclein. Cell 2012, 149, 1048–1059. [CrossRef]
- Johnson, J.T.; Awosiminiala, F.W.; Anumudu, C.K. Exploring Protein Misfolding and Aggregate Pathology in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Interventions. Applied Sciences 2025, 15, 10285. [CrossRef]
- Concha-Marambio, L.; Pritzkow, S.; Shahnawaz, M.; Farris, C.M.; Soto, C. Seed Amplification Assay for the Detection of Pathologic Alpha-Synuclein Aggregates in Cerebrospinal Fluid. Nat Protoc 2023, 18, 1179–1196. [CrossRef]
- Angelova, P.R.; Choi, M.L.; Berezhnov, A.V.; Horrocks, M.H.; Hughes, C.D.; De, S.; Rodrigues, M.; Yapom, R.; Little, D.; Dolt, K.S.; et al. Alpha Synuclein Aggregation Drives Ferroptosis: An Interplay of Iron, Calcium and Lipid Peroxidation. Cell Death Differ 2020, 27, 2781–2796. [CrossRef]
- Wang, X.; Becker, K.; Levine, N.; Zhang, M.; Lieberman, A.P.; Moore, D.J.; Ma, J. Pathogenic Alpha-Synuclein Aggregates Preferentially Bind to Mitochondria and Affect Cellular Respiration. acta neuropathol commun 2019, 7, 41. [CrossRef]
- Park, J.-H.; Burgess, J.D.; Faroqi, A.H.; DeMeo, N.N.; Fiesel, F.C.; Springer, W.; Delenclos, M.; McLean, P.J. Alpha-Synuclein-Induced Mitochondrial Dysfunction Is Mediated via a Sirtuin 3-Dependent Pathway. Mol Neurodegeneration 2020, 15, 5. [CrossRef]
- Thorne, N.J.; Tumbarello, D.A. The Relationship of Alpha-Synuclein to Mitochondrial Dynamics and Quality Control. Front. Mol. Neurosci. 2022, 15, 947191. [CrossRef]
- Choi, M.L.; Chappard, A.; Singh, B.P.; Maclachlan, C.; Rodrigues, M.; Fedotova, E.I.; Berezhnov, A.V.; De, S.; Peddie, C.J.; Athauda, D.; et al. Pathological Structural Conversion of α-Synuclein at the Mitochondria Induces Neuronal Toxicity. Nat Neurosci 2022, 25, 1134–1148. [CrossRef]
- Castellani, R.J.; Perry, G. Tau Biology, Tauopathy, Traumatic Brain Injury, and Diagnostic Challenges. Journal of Alzheimer’s Disease 2019, 67, 447–467. [CrossRef]
- Alavi Naini, S.M.; Soussi-Yanicostas, N. Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies? Oxidative Medicine and Cellular Longevity 2015, 2015, 1–17. [CrossRef]
- Song, L.; Wells, E.A.; Robinson, A.S. Critical Molecular and Cellular Contributors to Tau Pathology. Biomedicines 2021, 9, 190. [CrossRef]
- Hill, E.; Wall, M.J.; Moffat, K.G.; Karikari, T.K. Understanding the Pathophysiological Actions of Tau Oligomers: A Critical Review of Current Electrophysiological Approaches. Front. Mol. Neurosci. 2020, 13, 155. [CrossRef]
- Donison, N.; Palik, J.; Volkening, K.; Strong, M.J. Cellular and Molecular Mechanisms of Pathological Tau Phosphorylation in Traumatic Brain Injury: Implications for Chronic Traumatic Encephalopathy. Mol Neurodegeneration 2025, 20, 56. [CrossRef]
- Goedert, M.; Eisenberg, D.S.; Crowther, R.A. Propagation of Tau Aggregates and Neurodegeneration. Annu. Rev. Neurosci. 2017, 40, 189–210. [CrossRef]
- Usenovic, M.; Niroomand, S.; Drolet, R.E.; Yao, L.; Gaspar, R.C.; Hatcher, N.G.; Schachter, J.; Renger, J.J.; Parmentier-Batteur, S. Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells. J. Neurosci. 2015, 35, 14234–14250. [CrossRef]
- Niewiadomska, G.; Niewiadomski, W.; Steczkowska, M.; Gasiorowska, A. Tau Oligomers Neurotoxicity. Life 2021, 11, 28. [CrossRef]
- Höhn, A.; Tramutola, A.; Cascella, R. Proteostasis Failure in Neurodegenerative Diseases: Focus on Oxidative Stress. Oxidative Medicine and Cellular Longevity 2020, 2020, 1–21. [CrossRef]
- Ashok, A.; Andrabi, S.S.; Mansoor, S.; Kuang, Y.; Kwon, B.K.; Labhasetwar, V. Antioxidant Therapy in Oxidative Stress-Induced Neurodegenerative Diseases: Role of Nanoparticle-Based Drug Delivery Systems in Clinical Translation. Antioxidants 2022, 11, 408. [CrossRef]
- Bustamante-Barrientos, F.A.; Luque-Campos, N.; Araya, M.J.; Lara-Barba, E.; De Solminihac, J.; Pradenas, C.; Molina, L.; Herrera-Luna, Y.; Utreras-Mendoza, Y.; Elizondo-Vega, R.; et al. Mitochondrial Dysfunction in Neurodegenerative Disorders: Potential Therapeutic Application of Mitochondrial Transfer to Central Nervous System-Residing Cells. J Transl Med 2023, 21, 613. [CrossRef]
- Baev, A.Y.; Vinokurov, A.Y.; Novikova, I.N.; Dremin, V.V.; Potapova, E.V.; Abramov, A.Y. Interaction of Mitochondrial Calcium and ROS in Neurodegeneration. Cells 2022, 11, 706. [CrossRef]
- Kandel, R.; Jung, J.; Neal, S. Proteotoxic Stress and the Ubiquitin Proteasome System. Seminars in Cell & Developmental Biology 2024, 156, 107–120. [CrossRef]
- Shi, M.; Chai, Y.; Zhang, J.; Chen, X. Endoplasmic Reticulum Stress-Associated Neuronal Death and Innate Immune Response in Neurological Diseases. Front. Immunol. 2022, 12, 794580. [CrossRef]
- Olufunmilayo, E.O.; Gerke-Duncan, M.B.; Holsinger, R.M.D. Oxidative Stress and Antioxidants in Neurodegenerative Disorders. Antioxidants 2023, 12, 517. [CrossRef]
- Jomova, K.; Alomar, S.Y.; Alwasel, S.H.; Nepovimova, E.; Kuca, K.; Valko, M. Several Lines of Antioxidant Defense against Oxidative Stress: Antioxidant Enzymes, Nanomaterials with Multiple Enzyme-Mimicking Activities, and Low-Molecular-Weight Antioxidants. Arch Toxicol 2024, 98, 1323–1367. [CrossRef]
- Singh, A.; Kukreti, R.; Saso, L.; Kukreti, S. Oxidative Stress: A Key Modulator in Neurodegenerative Diseases. Molecules 2019, 24, 1583. [CrossRef]
- Afzal, S.; Abdul Manap, A.S.; Attiq, A.; Albokhadaim, I.; Kandeel, M.; Alhojaily, S.M. From Imbalance to Impairment: The Central Role of Reactive Oxygen Species in Oxidative Stress-Induced Disorders and Therapeutic Exploration. Front. Pharmacol. 2023, 14, 1269581. [CrossRef]
- Houldsworth, A. Role of Oxidative Stress in Neurodegenerative Disorders: A Review of Reactive Oxygen Species and Prevention by Antioxidants. Brain Communications 2023, 6, fcad356. [CrossRef]
- Castelli, V.; Benedetti, E.; Antonosante, A.; Catanesi, M.; Pitari, G.; Ippoliti, R.; Cimini, A.; d’Angelo, M. Neuronal Cells Rearrangement During Aging and Neurodegenerative Disease: Metabolism, Oxidative Stress and Organelles Dynamic. Front. Mol. Neurosci. 2019, 12, 132. [CrossRef]
- Verma, M.; Lizama, B.N.; Chu, C.T. Excitotoxicity, Calcium and Mitochondria: A Triad in Synaptic Neurodegeneration. Transl Neurodegener 2022, 11, 3. [CrossRef]
- Schmidt, M.F.; Gan, Z.Y.; Komander, D.; Dewson, G. Ubiquitin Signalling in Neurodegeneration: Mechanisms and Therapeutic Opportunities. Cell Death Differ 2021, 28, 570–590. [CrossRef]
- Ghemrawi, R.; Khair, M. Endoplasmic Reticulum Stress and Unfolded Protein Response in Neurodegenerative Diseases. IJMS 2020, 21, 6127. [CrossRef]
- Lozada Ortiz, J.; Betancor, M.; Pérez Lázaro, S.; Bolea, R.; Badiola, J.J.; Otero, A. Endoplasmic Reticulum Stress and Ubiquitin-Proteasome System Impairment in Natural Scrapie. Front. Mol. Neurosci. 2023, 16, 1175364. [CrossRef]
- Garland, E.F.; Hartnell, I.J.; Boche, D. Microglia and Astrocyte Function and Communication: What Do We Know in Humans? Front. Neurosci. 2022, 16, 824888. [CrossRef]
- Kuhn, S.; Gritti, L.; Crooks, D.; Dombrowski, Y. Oligodendrocytes in Development, Myelin Generation and Beyond. Cells 2019, 8, 1424. [CrossRef]
- Wendimu, M.Y.; Hooks, S.B. Microglia Phenotypes in Aging and Neurodegenerative Diseases. Cells 2022, 11, 2091. [CrossRef]
- Duncan, G.J.; Simkins, T.J.; Emery, B. Neuron-Oligodendrocyte Interactions in the Structure and Integrity of Axons. Front. Cell Dev. Biol. 2021, 9, 653101. [CrossRef]
- Lawrence, J.M.; Schardien, K.; Wigdahl, B.; Nonnemacher, M.R. Roles of Neuropathology-Associated Reactive Astrocytes: A Systematic Review. acta neuropathol commun 2023, 11, 42. [CrossRef]
- Andersen, J.V.; Schousboe, A. Milestone Review: Metabolic Dynamics of Glutamate and GABA Mediated Neurotransmission — The Essential Roles of Astrocytes. Journal of Neurochemistry 2023, 166, 109–137. [CrossRef]
- Joseph, U.G.; Oyovwi, M.O.; Jeroh, E.; Esuku, D.T.; Ben-Azu, B. Dysfunctional Astrocyte Metabolism: A Driver of Imbalanced Excitatory/Inhibitory Tone and Support for Therapeutic Intervention Targets. JMP 2025, 6, 12. [CrossRef]
- Taday, J.; Fróes, F.T.; Seady, M.; Gonçalves, C.A.; Leite, M.C. In Vitro Astroglial Dysfunction Induced by Neurotoxins: Mimicking Astrocytic Metabolic Alterations of Alzheimer’s Disease. Metabolites 2024, 14, 151. [CrossRef]
- Mi, Y.; Qi, G.; Vitali, F.; Shang, Y.; Raikes, A.C.; Wang, T.; Jin, Y.; Brinton, R.D.; Gu, H.; Yin, F. Loss of Fatty Acid Degradation by Astrocytic Mitochondria Triggers Neuroinflammation and Neurodegeneration. Nat Metab 2023, 5, 445–465. [CrossRef]
- Liang, K.X.; Chen, A.; Kianian, A.; Kristiansen, C.K.; Yangzom, T.; Furriol, J.; Høyland, L.E.; Ziegler, M.; Kråkenes, T.; Tzoulis, C.; et al. Activation of Neurotoxic Astrocytes Due to Mitochondrial Dysfunction Triggered by POLG Mutation. Int. J. Biol. Sci. 2024, 20, 2860–2880. [CrossRef]
- Stoklund Dittlau, K.; Terrie, L.; Baatsen, P.; Kerstens, A.; De Swert, L.; Janky, R.; Corthout, N.; Masrori, P.; Van Damme, P.; Hyttel, P.; et al. FUS-ALS hiPSC-Derived Astrocytes Impair Human Motor Units through Both Gain-of-Toxicity and Loss-of-Support Mechanisms. Mol Neurodegeneration 2023, 18, 5. [CrossRef]
- Killoy, K.M.; Harlan, B.A.; Pehar, M.; Vargas, M.R. FABP7 Upregulation Induces a Neurotoxic Phenotype in Astrocytes. Glia 2020, 68, 2693–2704. [CrossRef]
- Rojas-Cruz, A.F.; Martín-Jiménez, C.A.; González, J.; González-Giraldo, Y.; Pinzón, A.M.; Barreto, G.E.; Aristizábal-Pachón, A.F. Palmitic Acid Upregulates Type I Interferon–Mediated Antiviral Response and Cholesterol Biosynthesis in Human Astrocytes. Mol Neurobiol 2023, 60, 4842–4854. [CrossRef]
- He, Y.; Taylor, N.; Yao, X.; Bhattacharya, A. Mouse Primary Microglia Respond Differently to LPS and Poly(I:C) in Vitro. Sci Rep 2021, 11, 10447. [CrossRef]
- Ennerfelt, H.; Frost, E.L.; Shapiro, D.A.; Holliday, C.; Zengeler, K.E.; Voithofer, G.; Bolte, A.C.; Lammert, C.R.; Kulas, J.A.; Ulland, T.K.; et al. SYK Coordinates Neuroprotective Microglial Responses in Neurodegenerative Disease. Cell 2022, 185, 4135-4152.e22. [CrossRef]
- Han, X.; Xu, T.; Fang, Q.; Zhang, H.; Yue, L.; Hu, G.; Sun, L. Quercetin Hinders Microglial Activation to Alleviate Neurotoxicity via the Interplay between NLRP3 Inflammasome and Mitophagy. Redox Biology 2021, 44, 102010. [CrossRef]
- Xu, F.; Han, L.; Wang, Y.; Deng, D.; Ding, Y.; Zhao, S.; Zhang, Q.; Ma, L.; Chen, X. Prolonged Anesthesia Induces Neuroinflammation and Complement-Mediated Microglial Synaptic Elimination Involved in Neurocognitive Dysfunction and Anxiety-like Behaviors. BMC Med 2023, 21, 7. [CrossRef]
- Zhou, Y.; Chen, L.; Zheng, X.; Fang, Q.; Qian, Y.; Xu, T.; Liang, J.; Zhang, H.; Han, X.; Sun, L. Microglia Orchestrate Synaptic and Neuronal Stripping: Implication in Neuropsychiatric Lupus. J Cellular Molecular Medi 2024, 28, e18190. [CrossRef]
- Butler, C.A.; Popescu, A.S.; Kitchener, E.J.A.; Allendorf, D.H.; Puigdellívol, M.; Brown, G.C. Microglial Phagocytosis of Neurons in Neurodegeneration, and Its Regulation. Journal of Neurochemistry 2021, 158, 621–639. [CrossRef]
- Takata, F.; Nakagawa, S.; Matsumoto, J.; Dohgu, S. Blood-Brain Barrier Dysfunction Amplifies the Development of Neuroinflammation: Understanding of Cellular Events in Brain Microvascular Endothelial Cells for Prevention and Treatment of BBB Dysfunction. Front. Cell. Neurosci. 2021, 15, 661838. [CrossRef]
- Yang, G.; Xu, X.; Gao, W.; Wang, X.; Zhao, Y.; Xu, Y. Microglia-Orchestrated Neuroinflammation and Synaptic Remodeling: Roles of pro-Inflammatory Cytokines and Receptors in Neurodegeneration. Front. Cell. Neurosci. 2025, 19, 1700692. [CrossRef]
- Müller, L.; Di Benedetto, S. Neuroimmune Crosstalk in Chronic Neuroinflammation: Microglial Interactions and Immune Modulation. Front. Cell. Neurosci. 2025, 19, 1575022. [CrossRef]
- Kim, J.Y.; Kim, J.-H.; Kim, Y.-D.; Seo, J.H. High Vulnerability of Oligodendrocytes to Oxidative Stress Induced by Ultrafine Urban Particles. Antioxidants 2020, 10, 4. [CrossRef]
- Spaas, J.; Van Veggel, L.; Schepers, M.; Tiane, A.; Van Horssen, J.; Wilson, D.M.; Moya, P.R.; Piccart, E.; Hellings, N.; Eijnde, B.O.; et al. Oxidative Stress and Impaired Oligodendrocyte Precursor Cell Differentiation in Neurological Disorders. Cell. Mol. Life Sci. 2021, 78, 4615–4637. [CrossRef]
- Steudler, J.; Ecott, T.; Ivan, D.C.; Bouillet, E.; Walthert, S.; Berve, K.; Dick, T.P.; Engelhardt, B.; Locatelli, G. Autoimmune Neuroinflammation Triggers Mitochondrial Oxidation in Oligodendrocytes. Glia 2022, 70, 2045–2061. [CrossRef]
- Asadollahi, E.; Trevisiol, A.; Saab, A.S.; Looser, Z.J.; Dibaj, P.; Ebrahimi, R.; Kusch, K.; Ruhwedel, T.; Möbius, W.; Jahn, O.; et al. Oligodendroglial Fatty Acid Metabolism as a Central Nervous System Energy Reserve. Nat Neurosci 2024, 27, 1934–1944. [CrossRef]
- Frosch, M.; Shimizu, T.; Wogram, E.; Amann, L.; Gruber, L.; Groisman, A.I.; Fliegauf, M.; Schwabenland, M.; Chhatbar, C.; Zechel, S.; et al. Microglia–Neuron Crosstalk through Hex–GM2–MGL2 Maintains Brain Homeostasis. Nature 2025, 646, 913–924. [CrossRef]
- Liu, L.; Liu, J.; Bao, J.; Bai, Q.; Wang, G. Interaction of Microglia and Astrocytes in the Neurovascular Unit. Front. Immunol. 2020, 11, 1024. [CrossRef]
- Pang, Y.; Yang, J.; Liu, J.; Xie, Z.; Wang, J. Metabolic Interactions in the Brain: The Crucial Roles of Neurons, Astrocytes, and Microglia in Health and Disease. Front. Neurosci. 2026, 20, 1731771. [CrossRef]
- Singh, D. Astrocytic and Microglial Cells as the Modulators of Neuroinflammation in Alzheimer’s Disease. J Neuroinflammation 2022, 19, 206. [CrossRef]
- Kirkley, K.S.; Popichak, K.A.; Afzali, M.F.; Legare, M.E.; Tjalkens, R.B. Microglia Amplify Inflammatory Activation of Astrocytes in Manganese Neurotoxicity. J Neuroinflammation 2017, 14, 99. [CrossRef]
- Wilson, D.M.; Cookson, M.R.; Van Den Bosch, L.; Zetterberg, H.; Holtzman, D.M.; Dewachter, I. Hallmarks of Neurodegenerative Diseases. Cell 2023, 186, 693–714. [CrossRef]
- Sanghai, N.; Tranmer, G.K. Biochemical and Molecular Pathways in Neurodegenerative Diseases: An Integrated View. Cells 2023, 12, 2318. [CrossRef]
- Imam, F.; Saloner, R.; Vogel, J.W.; Krish, V.; Abdel-Azim, G.; Ali, M.; An, L.; Anastasi, F.; Bennett, D.; Pichet Binette, A.; et al. The Global Neurodegeneration Proteomics Consortium: Biomarker and Drug Target Discovery for Common Neurodegenerative Diseases and Aging. Nat Med 2025, 31, 2556–2566. [CrossRef]
- Myrou, A.; Barmpagiannos, K.; Ioakimidou, A.; Savopoulos, C. Molecular Biomarkers in Neurological Diseases: Advances in Diagnosis and Prognosis. IJMS 2025, 26, 2231. [CrossRef]
- Argueti-Ostrovsky, S.; Alfahel, L.; Kahn, J.; Israelson, A. All Roads Lead to Rome: Different Molecular Players Converge to Common Toxic Pathways in Neurodegeneration. Cells 2021, 10, 2438. [CrossRef]
- Muddapu, V.R.; Dharshini, S.A.P.; Chakravarthy, V.S.; Gromiha, M.M. Neurodegenerative Diseases – Is Metabolic Deficiency the Root Cause? Front. Neurosci. 2020, 14, 213. [CrossRef]
- Korczowska-Łącka, I.; Słowikowski, B.; Piekut, T.; Hurła, M.; Banaszek, N.; Szymanowicz, O.; Jagodziński, P.P.; Kozubski, W.; Permoda-Pachuta, A.; Dorszewska, J. Disorders of Endogenous and Exogenous Antioxidants in Neurological Diseases. Antioxidants 2023, 12, 1811. [CrossRef]
- Daponte, A.; Koros, C.; Skarlis, C.; Siozios, D.; Rentzos, M.; Papageorgiou, S.G.; Anagnostouli, M. Neurofilament Biomarkers in Neurology: From Neuroinflammation to Neurodegeneration, Bridging Established and Novel Analytical Advances with Clinical Practice. IJMS 2025, 26, 9739. [CrossRef]
- Noh, M.-Y.; Kwon, H.S.; Kwon, M.-S.; Nahm, M.; Jin, H.K.; Bae, J.; Kim, S.H. Biomarkers and Therapeutic Strategies Targeting Microglia in Neurodegenerative Diseases: Current Status and Future Directions. Mol Neurodegeneration 2025, 20, 82. [CrossRef]
- Kim, K.-H.; Yoo, M.; Choi, M.Y.; Yoo, B.C. A Practical Roadmap for Clinical Translation of Metabolic Biomarkers: A Review. IJMS 2026, 27, 2030. [CrossRef]
- Morén, C.; deSouza, R.M.; Giraldo, D.M.; Uff, C. Antioxidant Therapeutic Strategies in Neurodegenerative Diseases. IJMS 2022, 23, 9328. [CrossRef]
- Loh, J.S.; Mak, W.Q.; Tan, L.K.S.; Ng, C.X.; Chan, H.H.; Yeow, S.H.; Foo, J.B.; Ong, Y.S.; How, C.W.; Khaw, K.Y. Microbiota–Gut–Brain Axis and Its Therapeutic Applications in Neurodegenerative Diseases. Sig Transduct Target Ther 2024, 9, 37. [CrossRef]
- Ma, Y.; Song, R.; Duan, C. Mitochondrial Quality Control and Transfer Communication in Neurological Disorders and Neuroinflammation. Front. Immunol. 2025, 16, 1542369. [CrossRef]
- Solana-Manrique, C.; Sanz, F.J.; Martínez-Carrión, G.; Paricio, N. Antioxidant and Neuroprotective Effects of Carnosine: Therapeutic Implications in Neurodegenerative Diseases. Antioxidants 2022, 11, 848. [CrossRef]
- Cherneva, D.I.; Kehayova, G.; Dimitrova, S.; Dragomanova, S. The Central Nervous System Modulatory Activities of N-Acetylcysteine: A Synthesis of Two Decades of Evidence. CIMB 2025, 47, 710. [CrossRef]


| Class | Representative endogenous neurotoxin | Physiological role | Principal neurotoxic mechanisms | Major neurological associations | Ref. |
|---|---|---|---|---|---|
| Metabolic | Ammonia (NH3/NH4+) | Nitrogen metabolism and maintenance of amino acid homeostasis through the urea cycle | Astrocyte swelling via glutamine accumulation, mitochondrial dysfunction, oxidative/nitrosative stress, glutamate imbalance, cerebral edema | Hepatic encephalopathy, hyperammonemic encephalopathy, cerebral edema | [12,13,19] |
| Metabolic | Homocysteine | Involved in methylation reactions and one-carbon metabolism | NMDA receptor-mediated excitotoxicity, oxidative stress, endothelial dysfunction, blood-brain barrier disruption, apoptosis | Cognitive decline, vascular dementia, stroke, Alzheimer's disease | [11,14,21,25] |
| Metabolic | Advanced Glycation End-products (AGEs) | Low-level physiological protein glycation | RAGE activation, ROS generation, chronic inflammation, mitochondrial dysfunction, impaired autophagy | Diabetic neuropathy, Alzheimer's disease, vascular cognitive impairment | [29,30,32] |
| Neurotransmitter | Glutamate | Principal excitatory neurotransmitter involved in learning, memory, and synaptic plasticity | NMDA/AMPA receptor overactivation, Ca2+ overload, mitochondrial dysfunction, oxidative stress, excitotoxicity | Stroke, ALS, epilepsy, Alzheimer's disease | [34,36,39] |
| Neurotransmitter | Dopamine | Motor control, cognition, motivation, and reward signaling | Auto-oxidation to dopamine quinones, ROS generation, mitochondrial impairment | Parkinson's disease | [43,47] |
| Protein | Amyloid-β (Aβ) | Synaptic regulation and neuronal signaling at physiological concentrations | Toxic oligomer formation, synaptic dysfunction, membrane disruption | Alzheimer's disease | [52,53,56] |
| Protein | α-Synuclein | Synaptic vesicle trafficking and neurotransmitter release | Misfolding, oligomerization, mitochondrial dysfunction, vesicle trafficking defects | Parkinson's disease | [50,63] |
| Protein | Tau | Microtubule stabilization and axonal transport | Microtubule destabilization, toxic oligomer formation, impaired axonal transport | Tauopathies, Alzheimer's disease | [49,73,79,80] |
| Homeostatic disturbance | Representative biomarker(s) | Pathophysiological significance | Potential therapeutic strategies | Ref. |
|---|---|---|---|---|
| Nitrogen dysregulation | Blood ammonia, glutamine, plasma amino acid profile | Excess ammonia disrupts astrocyte metabolism, promotes glutamine accumulation, cerebral edema, mitochondrial dysfunction, and excitotoxicity | Nitrogen-lowering therapies (lactulose, rifaximin), ammonia scavengers, metabolic correction, liver support strategies | [130] |
| One-carbon metabolism dysfunction | Homocysteine, folate, vitamin B12, methylmalonic acid | Hyperhomocysteinemia induces oxidative stress, endothelial dysfunction, DNA hypomethylation, blood-brain barrier disruption, and neuronal apoptosis | Folate and vitamin B supplementation, homocysteine-lowering therapy, dietary intervention, methyl donor replacement | [131,134] |
| Oxidative stress and redox imbalance | Reduced glutathione (GSH), malondialdehyde (MDA), 4-HNE, 8-OHdG | Excess ROS/RNS causes lipid peroxidation, protein oxidation, DNA damage, mitochondrial dysfunction, and neuronal degeneration | Antioxidants, Nrf2 pathway activators, mitochondrial antioxidants, ROS scavengers, redox-modulating therapies | [87,138] |
| Neuroaxonal injury | Neurofilament light chain (NfL), GFAP, UCH-L1 | Reflects axonal degeneration, neuronal injury, disease progression, and treatment response across neurodegenerative disorders | Neuroprotective therapies, disease monitoring, biomarker-guided therapeutic assessment | [135] |
| Protein aggregation and impaired proteostasis | Amyloid-β, phosphorylated tau (p-tau), total tau, α-synuclein | Misfolded protein accumulation disrupts synaptic function, mitochondrial integrity, axonal transport, and proteostasis networks | Anti-aggregation therapies, monoclonal antibodies, autophagy enhancers, proteasome activation, proteostasis modulation | [130,136] |
| Neuroinflammation | TREM2, IL-1β, IL-6, TNF-α, TSPO-PET imaging | Persistent microglial activation promotes cytokine release, oxidative stress, synaptic dysfunction, and progressive neuronal injury | Microglial modulators, anti-inflammatory agents, cytokine-targeted therapies, neuroglial communication modulation | [136,139] |
| Mitochondrial dysfunction | Mitochondrial metabolites, mtDNA, ATP/ADP ratio, multi-omics signatures | Impaired oxidative phosphorylation results in ATP depletion, ROS overproduction, calcium imbalance, and activation of apoptotic pathways | Mitochondrial-targeted antioxidants, mitophagy enhancers, metabolic modulators, mitochondrial quality-control therapies | [138,140] |
| Integrated homeostatic dysfunction | Multi-omics biomarker panels (proteomics, metabolomics, transcriptomics, lipidomics) | Simultaneous disruption of metabolic, inflammatory, oxidative, and proteostatic pathways drives disease progression and inter-individual heterogeneity | Precision medicine, systems biology-guided interventions, AI-assisted biomarker integration, personalized combination therapies | [130,131,137] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).